Shares of Omeros Corporation (NASDAQ:OMER) rose 4.6% on Thursday . The company traded as high as $11.73 and last traded at $11.70, with a volume of 288,964 shares changing hands. The stock had previously closed at $11.19.

Several equities analysts recently issued reports on the company. Maxim Group reiterated a “buy” rating and issued a $30.00 price target on shares of Omeros Corporation in a report on Thursday. WBB Securities reiterated a “buy” rating and issued a $75.00 price target on shares of Omeros Corporation in a report on Tuesday, June 14th. Cantor Fitzgerald assumed coverage on Omeros Corporation in a report on Thursday, June 2nd. They issued a “buy” rating and a $21.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $62.00 price target on shares of Omeros Corporation in a report on Tuesday, May 10th. Finally, FBR & Co reiterated an “outperform” rating and issued a $38.00 price target on shares of Omeros Corporation in a report on Wednesday, June 29th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $38.22.

The stock has a 50-day moving average price of $11.01 and a 200 day moving average price of $12.08. The company’s market cap is $457.88 million.

Omeros Corporation (NASDAQ:OMER) last posted its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.11. During the same period in the prior year, the business earned ($0.51) earnings per share. The firm earned $7.40 million during the quarter, compared to the consensus estimate of $8.79 million. The business’s quarterly revenue was up 1797.4% compared to the same quarter last year. On average, equities analysts expect that Omeros Corporation will post ($1.76) EPS for the current year.

In other news, VP Marcia S. Kelbon sold 15,900 shares of the business’s stock in a transaction on Friday, July 15th. The stock was sold at an average price of $11.50, for a total transaction of $182,850.00. Following the completion of the transaction, the vice president now owns 179,497 shares of the company’s stock, valued at approximately $2,064,215.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Several institutional investors have bought and sold shares of the company. Nationwide Fund Advisors boosted its position in Omeros Corporation by 183.9% in the fourth quarter. Nationwide Fund Advisors now owns 69,700 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 45,145 shares during the period. California State Teachers Retirement System boosted its position in Omeros Corporation by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 70,144 shares of the biopharmaceutical company’s stock worth $1,103,000 after buying an additional 1,249 shares during the period. Mutual of America Capital Management LLC boosted its position in Omeros Corporation by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 116,171 shares of the biopharmaceutical company’s stock worth $1,827,000 after buying an additional 694 shares during the period. Finally, Bank of Montreal Can boosted its position in Omeros Corporation by 52.0% in the fourth quarter. Bank of Montreal Can now owns 1,327,706 shares of the biopharmaceutical company’s stock worth $20,885,000 after buying an additional 454,055 shares during the period.

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.